Exozymes CEO buys 855 shares, gets 8,841 grant

Rhea-AI Filing Summary

EXOZYMES INC. (EXOZ) reported that Chief Executive Officer Michael Heltzen increased his direct holdings of common stock through several transactions in August 2026. On August 25–26, 2026, he purchased a total of 855 shares in open market or private transactions at prices between $7.35 and $7.60 per share. On August 19, 2026, he also acquired 8,841 shares as a grant or award at $6.40 per share. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Buyer: 855 shares

Net Buy 6 txns

Insider Heltzen Michael

Role Chief Executive Officer

Bought 855 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4	$7.58	$30.32
Purchase	Common Stock	251	$7.35	$2K
Purchase	Common Stock	250	$7.60	$2K
Purchase	Common Stock	250	$7.52	$2K
Purchase	Common Stock	100	$7.50	$750.00
Grant/Award	Common Stock	8,841	$6.40	$57K

Holdings After Transaction: Common Stock — 14,453 shares (Direct)

Key Figures

Shares purchased in open market or private transactions: 855 shares Purchase price per share (low end): $7.35 per share Purchase price per share (high end): $7.60 per share +2 more

5 metrics

Shares purchased in open market or private transactions 855 shares Total common shares bought by the CEO on August 25–26, 2026

Purchase price per share (low end) $7.35 per share One of the reported purchase prices on August 26, 2026

Purchase price per share (high end) $7.60 per share One of the reported purchase prices on August 26, 2026

Shares acquired via grant or award 8,841 shares Common stock granted to the CEO on August 19, 2026

Grant reference price per share $6.40 per share Reported price associated with the August 19, 2026 grant or award

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did EXOZ (EXOZYMES INC.) report for its CEO in August 2026?

EXOZ reported that CEO Michael Heltzen purchased 855 shares of common stock in open market or private transactions on August 25–26, 2026 and received a grant of 8,841 shares on August 19, 2026.

At what prices did the EXOZ CEO buy EXOZYMES INC. common stock?

On August 25–26, 2026, CEO Michael Heltzen purchased EXOZ common stock at per-share prices ranging from $7.35 to $7.60 in open market or private transactions, as reported in the Form 4 filing.

How many EXOZ shares were granted to the EXOZYMES INC. CEO?

On August 19, 2026, CEO Michael Heltzen acquired 8,841 shares of EXOZYMES INC. common stock as a grant or award at a reported price of $6.40 per share.

Were the EXOZ CEO’s August 2026 transactions under a Rule 10b5-1 plan?

No. The Form 4 indicates that the Rule 10b5-1 trading plan box is not checked, so no Rule 10b5-1 plan is reported in connection with these August 2026 transactions.

What is the total number of EXOZ shares the CEO bought in the market?

Across five reported open market or private transactions on August 25–26, 2026, CEO Michael Heltzen purchased a total of 855 shares of EXOZYMES INC. common stock, according to the transaction summary.

Are the EXOZ CEO’s reported EXOZYMES INC. share holdings direct or indirect?

All reported August 2026 transactions for CEO Michael Heltzen involve direct ownership of EXOZYMES INC. common stock, as each entry is classified as directly held.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:33 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heltzen Michael

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE,

SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2026		P		4	A	$7.58	14,708	D
Common Stock	08/26/2026		P		251	A	$7.35	14,704	D
Common Stock	08/26/2026		P		250	A	$7.6	14,453	D
Common Stock	08/25/2026		P		250	A	$7.52	14,203	D
Common Stock	08/25/2026		P		100	A	$7.5	13,953	D
Common Stock	08/19/2026		A		8,841	A	$6.4	13,853	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Heltzen	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)